JOTROL is designed to overcome the historical challenges of resveratrol by significantly enhancing bioavailability while minimizing gastrointestinal side effects. The upcoming Phase 2a trial will ...
Skywatchers on Thursday evening, Feb. 6, will notice an eye-catching pairing-off between two of the brightest objects in the ...
Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL ™, Jupiter’s patented resveratrol-based ...
LLC ("Catalent") for the production of JOTROL ™ softgel capsules to support Jupiter’s upcoming Phase 2a clinical trial in Parkinson’s disease. Under the terms of the agreement, Catalent will ...
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical ...
I pick out North America’s celestial highlights for the week ahead (which also applies to northern hemisphere mid-northern ...
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...
Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL™, Jupiter’s patented resveratrol-based ...
February’s night sky gives us the bright trio of Mars, Jupiter and Venus, according to NASA skywatch experts. “Venus blazes ...
Jupiter Neurosciences Inc., a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback